This case could redefine the legal boundary between protecting pharmaceutical patents and allowing lower-cost generic drugs onto the market.
Jeremy Lowe
Advertisement
Jeremy Lowe, an attorney and leader of the Spencer Fane Hatch-Waxman and Biologics Litigation group.
Articles by Jeremy Lowe
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis to Layoff 322 NJ Employees: Report
2
Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement
3
Launch is Just the Beginning: Rare Disease Care Requires Durability
4
“AI as Reinvention”: Transforming the Business of Medicine
5